Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-503-085
Subject category: Marketing
Published by: Harvard Business Publishing
Originally published in: 2003
Version: 10 May 2006
Length: 21 pages
Data source: Field research

Abstract

The head of Cipla, a USD325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line could become unsaleable (given that it is based on product patents protected in industrialized countries). Describes Cipla's role in forcing global pharmaceutical companies to lower their prices for AIDS drugs.
Location:
Industry:
Size:
USD325 million revenues
Other setting(s):
2003

About

Abstract

The head of Cipla, a USD325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line could become unsaleable (given that it is based on product patents protected in industrialized countries). Describes Cipla's role in forcing global pharmaceutical companies to lower their prices for AIDS drugs.

Settings

Location:
Industry:
Size:
USD325 million revenues
Other setting(s):
2003

Related